To assume that growing a marketing presence in emerging markets automatically requires a global agency network is a flawed assumption.
Promotion in emerging markets offers several very important benefits to pharmaceutical companies:
Jay Carter
However, it is a flawed assumption to believe that growing a marketing presence in emerging markets automatically requires a global agency network.
Savvy global marketers should consider other options carefully. Here are four reasons why:
1. If the market you are entering is truly emerging, there is likely to be uneven quality among local agencies. It may sound appealing to hear a network executive claim uniform excellence. However, if there is even a 75 percent chance that the network you contract with has the best agency for a client's brand in a specific market (a spectacularly generous assumption), then the chances that six countries will all have the best agency with a single network is a whopping 18 percent. Simple statistics dictate that a global leader allow—even encourage—each affiliate to choose the agency that is the best fit locally.
2. As you build local affiliates, hire and develop independent leaders for them. This is an imperative for all of the organizations I work with on a daily basis. Taking away the ability of the affiliate general managers to select their own agencies reduces their ability to truly adapt to local needs.
3. The cost savings often cited by networks are based upon reducing the cost of creating six different campaigns, and not upon reducing local affiliate labor costs; each affiliate will still need to execute tactics locally.
4. For all these reasons, AbelsonTaylor advocates a simple brand book process: the pharmaceutical company's global marketing organization (often in partnership with the US affiliate, due to its dominant size) collaborates on the necessary insight work and brand development to create a global brand.
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.